SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
January 26, 2012
Date of Report (Date of earliest event
First China Pharmaceutical Group,
(Exact Name of Registrant as Specified in Charter)
|(State or Other Jurisdiction of Incorporation)
||(Commission File Number)
||(IRS Employer Identification No.)|
Number 504, West Ren Min Road,
Kunming City, Yunnan Province
People’s Republic of China, 650000
(Address of Principal Executive Offices)
(Registrant’s telephone number,
including area code)
(Former Name or Former Address, if Changed
Since Last Report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Section 2 – Financial Information
Item 2.02. Results of Operations and Financial Condition.
On January 26, 2012, First China Pharmaceutical
Group, Inc., a Nevada corporation (the “Company”) issued a press release reporting its projected financial sales results
for the year ended December 31, 2011.
A copy of the press release is attached hereto
as Exhibit 99.1 and incorporated herein by reference.
Section 9 – Financial Statements
Item 9.01. Financial Statements and Exhibits.
Press Release dated January 26, 2012
The information set forth under Item 2.02 of
this Form 8-K and Exhibit 99.1 attached hereto are furnished and shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, and shall not be deemed incorporated by reference in any filing with the Securities
and Exchange Commission under the Securities Exchange Act of 1934 or the Securities Act of 1933, whether made before or after the
date hereof and irrespective of any general incorporation by reference language in any filing.
Portions of this report constitute “forward-looking
statements” defined by federal law. Although the Company believes any such statements are based on reasonable
assumptions, there is no assurance that the actual outcomes will not be materially different. Any such statements are made in reliance
on the “safe harbor” protections provided under the Private Securities Litigation Reform Act of 1995. Additional information
about issues that could lead to material changes in the Company’s performance is contained in the Company’s filings
with the Securities and Exchange Commission and may be accessed at www.sec.gov.
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
||First China Pharmaceutical Group, Inc.|
| Dated: January 26, 2012
||/s/ Zhen Jiang Wang|
||Zhen Jiang Wang|
Chief Executive Officer